{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T18:40:01Z","timestamp":1745692801227,"version":"3.40.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s13555-025-01366-6","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T10:18:30Z","timestamp":1743675510000},"page":"1113-1134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Single-Injection Options for Administering a 320\u00a0mg Dose of Bimekizumab: 2\u00a0mL Safety Syringe and Auto-injector"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4082-6977","authenticated-orcid":false,"given":"Michael","family":"Sebastian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Bagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengt","family":"Hoepken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertram","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ceyhun","family":"Bicer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merran","family":"MacPherson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"issue":"1475","key":"1366_CR1","first-page":"1","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(1475):1\u201328.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1366_CR2","first-page":"636","volume":"73","author":"KM Luba","year":"2006","unstructured":"Luba KM, Stulberg DL. Chronic plaque psoriasis. Am Fam Physician. 2006;73(4):636\u201344.","journal-title":"Am Fam Physician"},{"issue":"3","key":"1366_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379\u201390.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1366_CR4","first-page":"127","volume":"12","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M. Bimekizumab for the treatment of psoriasis: a review of the current knowledge. Psoriasis (Auckl). 2022;12:127\u201337.","journal-title":"Psoriasis (Auckl)"},{"issue":"11","key":"1366_CR5","first-page":"1","volume":"2020","author":"R Adams","year":"1894","unstructured":"Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 1894;2020(11):1\u201310.","journal-title":"Front Immunol"},{"issue":"4","key":"1366_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","volume":"77","author":"S Glatt","year":"2018","unstructured":"Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1366_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.36849\/JDD.6274","volume":"21","author":"J Bagel","year":"2022","unstructured":"Bagel J, Tatla D, Hellot S, et al. Bimekizumab self-injection devices: two multicenter, randomized, open-label studies on self-administration by patients with psoriasis. J Drugs Dermatol. 2022;21(2):162\u201371.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"1366_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","volume":"385","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130\u201341.","journal-title":"N Engl J Med"},{"issue":"10273","key":"1366_CR9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase\u00a03 trial. Lancet. 2021;397(10273):487\u201398.","journal-title":"Lancet"},{"issue":"10273","key":"1366_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","volume":"397","author":"KB Gordon","year":"2021","unstructured":"Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase\u00a03 trial. Lancet. 2021;397(10273):475\u201386.","journal-title":"Lancet"},{"issue":"2","key":"1366_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142\u201352.","journal-title":"N Engl J Med"},{"issue":"4","key":"1366_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/bjd\/ljad429","volume":"190","author":"KB Gordon","year":"2024","unstructured":"Gordon KB, Langley RG, Warren RB, et al. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3\u00a0years of treatment in randomized phase\u00a0III trials. Br J Dermatol. 2024;190(4):477\u201385.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1366_CR13","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/bjd\/ljad035","volume":"188","author":"B Strober","year":"2023","unstructured":"Strober B, Tada Y, Mrowietz U, et al. Bimekizumab maintenance of response through 3\u00a0years in patients with moderate-to-severe plaque psoriasis: results from the BE\u00a0BRIGHT open-label extension trial. Br J Dermatol. 2023;188(6):749\u201359.","journal-title":"Br J Dermatol"},{"doi-asserted-by":"crossref","unstructured":"Gordon KB, Tha\u00e7i D, Gooderham M, et al. 52671 Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4\u00a0years of treatment in 5 phase\u00a03\/3b clinical trials. J Am Acad Dermatol. 2024;91(3):AB145.","key":"1366_CR14","DOI":"10.1016\/j.jaad.2024.07.577"},{"doi-asserted-by":"crossref","unstructured":"Blauvelt A, Foley P, Langley R, et al. Bimekizumab 4-year maintenance of responses in week\u00a016 responders with moderate to severe plaque psoriasis: results from the BE\u00a0BRIGHT open-label extension phase\u00a03 trial. Presented at Fall Clinical 2024. 2024.","key":"1366_CR15","DOI":"10.25251\/skin.8.supp.437"},{"issue":"1","key":"1366_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/rmdopen-2023-003855","volume":"10","author":"LC Coates","year":"2024","unstructured":"Coates LC, Landew\u00e9 R, McInnes IB, et al. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase\u00a0III BE COMPLETE study and its open-label extension BE VITAL. RMD Open. 2024;10(1):1\u201314.","journal-title":"RMD Open"},{"issue":"11","key":"1366_CR17","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1136\/ard-2023-224431","volume":"82","author":"CT Ritchlin","year":"2023","unstructured":"Ritchlin CT, Coates LC, McInnes IB, et al. Bimekizumab treatment in biologic DMARD-na\u00efve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase\u00a0III, randomised, placebo-controlled, active reference BE OPTIMAL study. Ann Rheum Dis. 2023;82(11):1404\u201314.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1366_CR18","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s40744-024-00708-8","volume":"11","author":"PJ Mease","year":"2024","unstructured":"Mease PJ, Merola JF, Tanaka Y, et al. Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase\u00a03 studies. Rheumatol Ther. 2024;11(5):1363\u201382.","journal-title":"Rheumatol Ther"},{"issue":"10443","key":"1366_CR19","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase\u00a03 trials. Lancet. 2024;403(10443):2504\u201319.","journal-title":"Lancet"},{"issue":"2","key":"1366_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/ard-2023-224803","volume":"83","author":"X Baraliakos","year":"2024","unstructured":"Baraliakos X, Deodhar A, van der Heijde D, et al. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase\u00a03 BE MOBILE 1 and BE MOBILE 2 studies. Ann Rheum Dis. 2024;83(2):199\u2013213.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1366_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/ard-2022-223595","volume":"82","author":"D van der Heijde","year":"2023","unstructured":"van der Heijde D, Deodhar A, Baraliakos X, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase\u00a03 randomised controlled trials. Ann Rheum Dis. 2023;82(4):515\u201326.","journal-title":"Ann Rheum Dis"},{"issue":"16\u201317","key":"1366_CR22","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/1750743X.2024.2401308","volume":"16","author":"RB Shams","year":"2024","unstructured":"Shams RB, Sayed CJ. Bimekizumab for the treatment of hidradenitis suppurativa. Immunotherapy. 2024;16(16\u201317):1005\u201313.","journal-title":"Immunotherapy"},{"unstructured":"UCB. Prescribing information: Bimekizumab. 2023. https:\/\/www.ucb-usa.com\/bimzelx-prescribing-information.pdf. Accessed 14 Nov 2024.","key":"1366_CR23"},{"issue":"1","key":"1366_CR24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/10717544.2019.1587043","volume":"26","author":"BJF van den Bemt","year":"2019","unstructured":"van den Bemt BJF, Gettings L, Doma\u0144ska B, Bruggraber R, Mountian I, Kristensen LE. A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 2019;26(1):384\u201392.","journal-title":"Drug Deliv"},{"issue":"5","key":"1366_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/cia2.12313","volume":"6","author":"M Ito","year":"2023","unstructured":"Ito M, Kamata M, Ishikawa T, et al. Improvements in self-confidence and satisfaction with self-injection after introducing self-injection of dupilumab in patients with atopic dermatitis. J Cutan Immunol Allergy. 2023;6(5):152\u20138.","journal-title":"J Cutan Immunol Allergy"},{"key":"1366_CR26","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.2147\/PPA.S413871","volume":"17","author":"A Onishi","year":"2023","unstructured":"Onishi A, Kaizu M, Shirasugi I, et al. Demographic, physical, and psychological determinants of patient experience with subcutaneous self-injection in patients with rheumatoid arthritis: structural equation modeling approach. Patient Prefer Adher. 2023;17:1551\u20139.","journal-title":"Patient Prefer Adher"},{"key":"1366_CR27","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2147\/PPA.S203775","volume":"13","author":"M Boeri","year":"2019","unstructured":"Boeri M, Szegvari B, Hauber B, et al. From drug-delivery device to disease management tool: a study of preferences for enhanced features in next-generation self-injection devices. Patient Prefer Adher. 2019;13:1093\u2013110.","journal-title":"Patient Prefer Adher"},{"issue":"2","key":"1366_CR28","first-page":"1","volume":"9","author":"D Keininger","year":"2011","unstructured":"Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ). Health Qual Life Outcomes. 2011;9(2):1\u201311.","journal-title":"Health Qual Life Outcomes"},{"unstructured":"European Medicines Agency (EMA). Guidelines on the investigation of bioequivalence. 2010. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 15 Nov 2024.","key":"1366_CR29"},{"issue":"4","key":"1366_CR30","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/wics.1310","volume":"6","author":"SC Chow","year":"2014","unstructured":"Chow SC. Bioavailability and bioequivalence in drug development. Wiley Interdiscip Rev Comput Stat. 2014;6(4):304\u201312.","journal-title":"Wiley Interdiscip Rev Comput Stat"},{"issue":"8038","key":"1366_CR31","first-page":"1","volume":"28","author":"M Stielow","year":"2023","unstructured":"Stielow M, Witczy\u0144ska A, Kubry\u0144 N, Fija\u0142kowski \u0141, Nowaczyk J, Nowaczyk A. The bioavailability of drugs-the current state of knowledge. Molecules. 2023;28(8038):1\u201319.","journal-title":"Molecules"},{"unstructured":"Nagadurga D. Bioavailability and bioequivalence studies. Pharmaceutical formulation design: recent practices. 2020.","key":"1366_CR32"},{"unstructured":"ClinicalTrials.gov. A study to evaluate the safe and effective use of the prefilled safety syringe or the auto-injector for the subcutaneous self-injection of bimekizumab solution by subjects with moderate to severe chronic plaque psoriasis (PSO). NCT03766685. 2023. https:\/\/clinicaltrials.gov\/study\/NCT03766685?term=NCT03766685&rank=1. Accessed 15 Nov 2024.","key":"1366_CR33"},{"unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (BE\u00a0BRIGHT). NCT03598790. 2023. https:\/\/clinicaltrials.gov\/study\/NCT03598790?term=NCT03598790&rank=1. Accessed 15 Nov 2024.","key":"1366_CR34"},{"unstructured":"US Food and Drug Administration (FDA). Statistical approaches to establishing bioequivalence. 2001. https:\/\/www.fda.gov\/media\/70958\/download. Accessed 5 Dec 2024.","key":"1366_CR35"},{"unstructured":"Health Canada. Guidance document: conduct and analysis of comparative bioavailability studies. 2023. https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/drugs-health-products\/drug-products\/applications-submissions\/guidance-documents\/bioavailability-bioequivalence\/conduct-analysis-comparative.pdf. Accessed 5 Dec 2024.","key":"1366_CR36"},{"issue":"8","key":"1366_CR37","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1177\/1474515120939007","volume":"19","author":"E Lambrinou","year":"2020","unstructured":"Lambrinou E, Kyriakou M, Lakatamitou I, et al. An integrative review on facilitators and barriers in delivering and managing injectable therapies in chronic conditions: a part of the ACNAP project \u2018injectable medicines among patients with cardiovascular conditions.\u2019 Eur J Cardiovasc Nurs. 2020;19(8):663\u201380.","journal-title":"Eur J Cardiovasc Nurs"},{"key":"1366_CR38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/DHPS.S290771","volume":"13","author":"J Tornero Molina","year":"2021","unstructured":"Tornero Molina J, L\u00f3pez Robledillo JC, Casamira RN. Potential benefits of the self-administration of subcutaneous methotrexate with autoinjector devices for patients: a review. Drug Healthc Patient Saf. 2021;13:81\u201394.","journal-title":"Drug Healthc Patient Saf"},{"issue":"2","key":"1366_CR39","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s40744-017-0080-4","volume":"4","author":"M Schiff","year":"2017","unstructured":"Schiff M, Saunderson S, Mountian I, Hartley P. Chronic disease and self-injection: ethnographic investigations into the patient experience during treatment. Rheumatol Ther. 2017;4(2):445\u201363.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"1366_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/17425247.2016.1256283","volume":"14","author":"B Doma\u0144ska","year":"2017","unstructured":"Doma\u0144ska B, VanLunen B, Peterson L, Mountian I, Schiff M. Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis. Expert Opin Drug Deliv. 2017;14(1):15\u201322.","journal-title":"Expert Opin Drug Deliv"},{"issue":"6","key":"1366_CR41","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1097\/00000542-200112000-00013","volume":"95","author":"CA Bodian","year":"2001","unstructured":"Bodian CA, Freedman G, Hossain S, Eisenkraft JB, Beilin Y. The Visual Analog Scale for pain: clinical significance in postoperative patients. Anesthesiology. 2001;95(6):1356\u201361.","journal-title":"Anesthesiology"},{"issue":"7","key":"1366_CR42","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1526-5900(03)00716-8","volume":"4","author":"MP Jensen","year":"2003","unstructured":"Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. J Pain. 2003;4(7):407\u201314.","journal-title":"J Pain"},{"unstructured":"UCB. Prescribing information: Bimekizumab for HS. 2024. https:\/\/www.ucbconnect.com\/sites\/default\/files\/2024-06\/API_Bimzelx_GB.pdf#:~:text=Hidradenitis%20suppurativa%3A%20320%20mg%20%28given%20as%202%20subcutaneous,thereafter.Renal%20or%20hepatic%20impairment%3A%20No%20dose%20adjustment%20needed. Accessed 14 Nov 2024.","key":"1366_CR43"},{"issue":"11","key":"1366_CR44","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1007\/s12325-023-02671-2","volume":"40","author":"A Antalfy","year":"2023","unstructured":"Antalfy A, Berman K, Everitt C, Alten R, Latymer M, Godfrey CM. The adherence and outcomes benefits of using a connected, reusable auto-injector for self-injecting biologics: a narrative review. Adv Ther. 2023;40(11):4758\u201376.","journal-title":"Adv Ther"},{"issue":"1","key":"1366_CR45","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s12325-017-0645-1","volume":"35","author":"B Doma\u0144ska","year":"2018","unstructured":"Doma\u0144ska B, Stumpp O, Poon S, Oray S, Mountian I, Pichon C. Using patient feedback to optimize the design of a certolizumab pegol electromechanical self-injection device: insights from human factors studies. Adv Ther. 2018;35(1):100\u201315.","journal-title":"Adv Ther"},{"issue":"10136","key":"1366_CR46","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273\u201384.","journal-title":"Lancet"},{"issue":"3","key":"1366_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001321","volume":"6","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, Michaud K, Nowak M, et al. Patient\u2019s experience of psoriatic arthritis: a conceptual model based on qualitative interviews. RMD Open. 2020;6(3):e001321.","journal-title":"RMD Open"},{"issue":"1","key":"1366_CR48","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","volume":"3","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Rheumatol Ther. 2016;3(1):91\u2013102.","journal-title":"Rheumatol Ther"},{"issue":"10","key":"1366_CR49","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u201370.","journal-title":"N Engl J Med"},{"issue":"1","key":"1366_CR50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/1756-185X.14241","volume":"25","author":"B Candiri","year":"2022","unstructured":"Candiri B, Talu B, Demirtas Karaoba D, Ozaltin GE, Yolbas S. Effect of psoriatic arthritis on the strength, proprioception, skill, coordination, and functional condition of the hand. Int J Rheum Dis. 2022;25(1):47\u201355.","journal-title":"Int J Rheum Dis"},{"key":"1366_CR51","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s10067-017-3756-9","volume":"36","author":"D Palamar","year":"2017","unstructured":"Palamar D, Er G, Terlemez R, Ustun I, Can G, Saridogan M. Disease activity, handgrip strengths, and hand dexterity in patients with rheumatoid arthritis. Clin Rheumatol. 2017;36:2201\u20138.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"1366_CR52","doi-asserted-by":"publisher","first-page":"14565","DOI":"10.1038\/s41598-023-39198-z","volume":"13","author":"V Gracia-Ib\u00e1\u00f1ez","year":"2023","unstructured":"Gracia-Ib\u00e1\u00f1ez V, Jarque-Bou NJ, Bayarri-Porcar V, et al. Impact of hand osteoarthritis in women on maximal forces in six different grasp types. Sci Rep. 2023;13(1):14565.","journal-title":"Sci Rep"},{"issue":"4","key":"1366_CR53","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/1756-185X.13803","volume":"23","author":"F Salaffi","year":"2020","unstructured":"Salaffi F, Di Carlo M, Farah S, Carotti M. Adherence to subcutaneous anti-TNF\u03b1 agents in patients with rheumatoid arthritis is largely influenced by pain and skin sensations at the injection site. Int J Rheum Dis. 2020;23(4):480\u20137.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"1366_CR54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.gastrohep.2019.06.008","volume":"43","author":"C Gely","year":"2020","unstructured":"Gely C, Mar\u00edn L, Gordillo J, et al. Impact of pain associated with the subcutaneous administration of adalimumab. Gastroenterol Hepatol. 2020;43(1):9\u201313.","journal-title":"Gastroenterol Hepatol"},{"issue":"4","key":"1366_CR55","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40744-020-00245-0","volume":"7","author":"A St Clair-Jones","year":"2020","unstructured":"St Clair-Jones A, Prignano F, Goncalves J, Paul M, Sewerin P. Understanding and minimising injection-site pain following subcutaneous administration of biologics: a narrative review. Rheumatol Ther. 2020;7(4):741\u201357.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"1366_CR56","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15285","volume":"35","author":"B Sigurgeirsson","year":"2022","unstructured":"Sigurgeirsson B, Browning J, Tyring S, et al. Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial. Dermatol Ther. 2022;35(3):e15285.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1366_CR57","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1080\/09546634.2021.1914812","volume":"33","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Gordon KB, Lee P, et al. Efficacy, safety, usability, and acceptability of risankizumab 150\u00a0mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. J Dermatol Treat. 2022;33(4):2085\u201393.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"1366_CR58","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1080\/09546634.2021.1902925","volume":"33","author":"B Sigurgeirsson","year":"2022","unstructured":"Sigurgeirsson B, Sch\u00e4kel K, Hong CH, et al. Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300\u00a0mg in patients with moderate to severe plaque psoriasis: results from the phase\u00a03 randomized, double-blind, placebo-controlled ALLURE study. J Dermatol Treat. 2022;33(3):1718\u201326.","journal-title":"J Dermatol Treat"},{"issue":"01","key":"1366_CR59","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.30574\/ijsra.2024.11.1.0339","volume":"11","author":"C Okolo","year":"2024","unstructured":"Okolo C, Olorunsogo T, Babawarun O. Cultural variability in pain perception: a review of cross-cultural studies. Int J Sci Res Arc. 2024;11(01):2550\u20136.","journal-title":"Int J Sci Res Arc"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01366-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01366-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01366-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T18:02:23Z","timestamp":1745690543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01366-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1366"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01366-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2025,3,29]]},"assertion":[{"value":"22 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Michael Sebastian: Cooperations with the following companies: AbbVie, Affibody, Allergan, Alumis, Almirall, Apogee, AstraZeneca, August Wolff, Boehringer Ingelheim, Bristol Myers Squibb, Dermapharm, Dermira, Galderma, Incyte, Ipsen, Janssen-Cilag, LEO Pharma, MedImmune, Menlo Therapeutics, Moonlake, MSD, Mundipharma, Novartis, Pfizer, Regeneron, Sanofi, Takeda, and UCB Pharma; Jerry Bagel: Speaker, investigator and\/or consultant for AbbVie, Celgene, Eli Lilly and Company, LEO Pharma, Novartis, Ortho Dermatologics; research funds payable to Psoriasis Treatment Center from AbbVie, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, CorEvitas, Dermavant Sciences, Dermira, Eli Lilly and Company, Glenmark Pharmaceuticals, Janssen, Kadmon Corporation, LEO Pharma, Lycera, Menlo Therapeutics, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sun Pharma, Taro, and UCB; consultant fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Novartis, Sun Pharma, and UCB; and fees for speaking from AbbVie, Celgene, Eli Lilly and Company, Janssen, and Novartis; Bengt Hoepken, Bertram Knapp, Merran MacPherson: employees of UCB; Ceyhun Bicer: statistical consultant at UCB; Richard G. Langley: Principal investigator for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, LEO Pharma, Merck, Novartis, Pfizer, and UCB Pharma; served on scientific advisory boards for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, LEO Pharma, Merck, Novartis, Pfizer, and UCB Pharma; provided lectures for AbbVie, Amgen, Celgene, Eli Lilly, LEO Pharma, Merck, Novartis, and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All studies were conducted in accordance with the principles of the Declaration of Helsinki and were approved by an independent review board and independent ethics committee. All participants provided informed written consent. All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}